Expert review of anticancer therapy · 2025
EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Su Bosheng, Xie Yuwei, Zhou Yingnan, Shi Fumin, Wang Jia, Xu Long
Аннотация
BACKGROUND: Patients with advanced EGFR-mutant NSCLC and high PD-L1 expression (TPS ≥50%) typically respond poorly to EGFR-TKI monotherapy. We compared EGFR-TKI plus chemotherapy versus TKI alone in this population.
RESEARCH DESIGN AND METHODS: This retrospective study included 212 patients receiving first-line osimertinib with chemotherapy (n = 98) or as monotherapy (n = 114). Primary endpoint was progression-free survival (PFS).
RESULTS: Combination therapy significantly improved median PFS overall (22.5 vs 13.8 months; HR = 0.513, 95% CI:0.372-0.803; p < 0.001) and in PD-L1-high patients (18.2 vs 7.9 months; HR = 0.356, 95% CI:0.195-0.641; p = 0.001). ORR was higher with combination therapy (67.3% vs 36.8%; p < 0.001). Grade ≥3 adverse events were more common with combination therapy (45.9% vs 22.8%) but were primarily manageable hematological events.
CONCLUSIONS: Osimertinib-chemotherapy combination showed superior efficacy versus monotherapy in EGFR-mutant, PD-L1-high NSCLC, with manageable safety. Our real-world findings validate and extend the FLAURA2 results by highlighting this high-risk subgroup as one that may derive particular benefit from first-line combination therapy.
RESEARCH DESIGN AND METHODS: This retrospective study included 212 patients receiving first-line osimertinib with chemotherapy (n = 98) or as monotherapy (n = 114). Primary endpoint was progression-free survival (PFS).
RESULTS: Combination therapy significantly improved median PFS overall (22.5 vs 13.8 months; HR = 0.513, 95% CI:0.372-0.803; p < 0.001) and in PD-L1-high patients (18.2 vs 7.9 months; HR = 0.356, 95% CI:0.195-0.641; p = 0.001). ORR was higher with combination therapy (67.3% vs 36.8%; p < 0.001). Grade ≥3 adverse events were more common with combination therapy (45.9% vs 22.8%) but were primarily manageable hematological events.
CONCLUSIONS: Osimertinib-chemotherapy combination showed superior efficacy versus monotherapy in EGFR-mutant, PD-L1-high NSCLC, with manageable safety. Our real-world findings validate and extend the FLAURA2 results by highlighting this high-risk subgroup as one that may derive particular benefit from first-line combination therapy.
Предметные рубрики MeSH
HumansCarcinoma, Non-Small-Cell LungRetrospective StudiesErbB ReceptorsFemaleMaleLung NeoplasmsAcrylamidesMiddle AgedAniline CompoundsAgedAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsB7-H1 AntigenProgression-Free SurvivalMutationAdultAged, 80 and overSurvival RateIndolesPyrimidines